Stay updated on Nivolumab + HF10 for Resectable Melanoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab + HF10 for Resectable Melanoma Clinical Trial page.

Latest updates to the Nivolumab + HF10 for Resectable Melanoma Clinical Trial page
- Check4 days agoNo Change Detected
- Check12 days agoChange DetectedMinor metadata updates: the page now shows a new revision label (v3.4.2) and adds the Melanoma keyword along with related topics such as MedlinePlus Genetics. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check20 days agoChange DetectedRevision updated to v3.4.1. Melanoma and related topics (MedlinePlus Genetics) were removed, and the reference to Revision: v3.4.0 was deleted.SummaryDifference0.2%

- Check34 days agoChange DetectedThe page now lists Melanoma as a topic and adds a related topics link to MedlinePlus Genetics. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check41 days agoChange DetectedThe page now includes a new revision note (Revision: v3.3.4) and removes certain topics (Melanoma and MedlinePlus Genetics) as well as the prior revision tag (Revision: v3.3.3). These updates are metadata/navigation changes and do not affect the trial's core details, eligibility criteria, or results.SummaryDifference0.2%

- Check55 days agoChange DetectedAdded Melanoma as a related topic and MedlinePlus Genetics as related topics on the page; these are contextual and do not alter core study content, eligibility criteria, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check63 days agoChange DetectedAdded Utah to the Locations section and updated the revision to v3.3.3. Removed Utah Locations and several related topics, including HHS Vulnerability Disclosure, MedlinePlus Genetics, and Melanoma.SummaryDifference0.4%

Stay in the know with updates to Nivolumab + HF10 for Resectable Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab + HF10 for Resectable Melanoma Clinical Trial page.